Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 167, Issue -, Pages 37-48Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.01.082
Keywords
N-indanyl benzamides; ROR gamma t inverse agonists; Th17 cells; Autoimmune diseases; Binding modes
Categories
Funding
- National Science Foundation of China [81573276, 81874287]
- Shanghai Bio-pharmaceutical Science and Technology Supporting Plan [17431902100]
- National Science & Technology Major Project Key New Drug Creation and Manufacturing Program of China [:2018ZX09711002]
- Fudan-SIMM Joint Research Fund [FU-SIMM20174007]
Ask authors/readers for more resources
The retinoic acid receptor-related orphan receptor-gamma-t (ROR gamma t) is a promising therapeutic target for treatment of Th17 cell-mediated autoimmune diseases. Based on a scaffold hopping/conformational restriction strategy, a series of N-indanyl benzamides as novel ROR gamma t inverse agonists was discovered. Exploration of structure-activity relationship on the piperazine ring, benzoyl moiety and cyclopentyl moiety of N-indanyl benzamides 2a and 2d led to identification of potent ROR gamma t inverse agonists. Compound 5c with (S)-enantiomer was found having an IC50 of 153.7 nM in Fluorescence Resonance Energy Transfer (FRET) assay, and an IC50 of 47.1 nM in mouse Th17 cell differentiation assay, which represents a promising starting point for developing potent small molecule ROR gamma t inverse agonists. Binding modes of the two enantiomers 5c and 5d in ROR gamma t ligand binding domain were also discussed. (C) 2019 Published by Elsevier Masson SAS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available